Why IMU is a multi multi bagger, page-22640

I believe all-or-nothing expectations when making a binary dose-response comparison of partial versus complete response results is dangerous and does little but support a more often than not irrational market. I expect that challenges have and are being presented when collecting data across what is a relatively small sample size with infinite limiting behaviors which in turn makes providing exact timelines difficult when balancing shareholder needs and patient well-being. Although personally comfortable of IMU milestones and performance LC to date, it has undoubtedly been a tough few months for many, and could get tougher again, investor and patient alike. For me though this makes the next data cut very interesting as an opportunity to hopefully further review potency and efficacy responses on a quantal dose-response basis independent of any re-rate expectations. Long live IMU. My opinion only of course !